search
Back to results

The Effectivity of the Mobile App "HARKIT I-Care" in Secondary Prevention in Post-ACS Patients

Primary Purpose

Acute Coronary Syndrome

Status
Recruiting
Phase
Not Applicable
Locations
Indonesia
Study Type
Interventional
Intervention
HARKIT I-Care Application
Sponsored by
National Cardiovascular Center Harapan Kita Hospital Indonesia
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Coronary Syndrome focused on measuring Acute Coronary Syndrome, Mobile Health, Secondary Prevention

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Acute Coronary Syndrome (ACS) patients, either ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina pectoris (UAP) who have or have not undergone revascularization treatment Exclusion Criteria: Does not have or know how to operate smartphone Unable to perform a smartphone due to hearing, vision, or cognitive impairment Withdrawn consent from the research

Sites / Locations

  • National Cardiovascular Center Harapan Kita Hospital IndonesiaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

No Intervention

Experimental

Arm Label

Control

I-Care

Arm Description

Subjects in the control group will receive education on the day of enrolment in NCCHK. Subjects are instructed to take medications and conduct hospital visits as usual.

Subjects will be instructed to download the "HARKIT I-Care" app from the google play store on their smartphones. Then, they will be guided to create an account and explained how to use the application, including how to log their progress (laboratory parameters and exercise tracking) and how to see messages from their physician. All follow-ups regarding treatment progress, education, and reminders will be done through the app. Patients are directed to conduct hospital visits once per month, where patients will be prescribed cardiovascular medications according to their current condition.

Outcomes

Primary Outcome Measures

Major Adverse Cardiovascular Event
Major Adverse Cardiovascular Event (MACE) is described as all cardiovascular deaths, myocardial infarction, stroke, heart failure hospitalization, and revascularization event
All-Cause Mortality
All deaths, both cardiovascular mortality and non-cardiovascular mortality
Cardiovascular Mortality
We defined Cardiovascular Mortality as all deaths, excluding deaths which etiology definitely was a non-cardiovascular etiology
Rehospitalization
Rehospitalization is defined as all unplanned visits to the hospital, both to the emergency department or inpatient ward, with the diagnosis of cardiovascular diseases and related complications (bleeding, hypertension crisis, and hyperglycemia crisis). Events of the planned visit to the hospital are excluded.

Secondary Outcome Measures

Smoking Cessation
Smoking cessation is defined as the number of patients who at the time of recruitment are active smokers and at the time of final follow up the patients have stopped smoking for at least one month
Smoking Relapse
Smoking relapse is defined as patient who at the time of recruitment is an ex smoker (defined as at least 1 month smoke-free before the time of recruitment) but during follow up time picks up smoking again
Total Cholesterol Level (mg/dL)
Total Cholesterol level (in mg/dL) is measured at NCCHK laboratory
HDL Level (mg/dL)
HDL level (in mg/dL) is measured at NCCHK laboratory
LDL Level (mg/dL)
LDL level (in mg/dL) is measured at NCCHK laboratory
Triglyceride Level (mg/dL)
Triglyceride level (in mg/dL) is measured at NCCHK laboratory
Blood Glucose Level (mg/dL)
Blood Glucose Level (in mg/dL) is measured at NCCHK laboratory, including fasting blood glucose and postprandial blood glucose
HbA1c (%)
HbA1c (in %) is measured at NCCHK laboratory
SF-36 Quality of Life Questionnaire
SF 36 is a questionnaire developed to assess the Quality of Life in patients. Each question is scored from 0-100 and transformed into different scales (Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Energy/fatigue, emotional well-being, social functioning, pain, and general health).
Physical activity level
Physical activity level is measured using the International Physical Activity Questionnaire (IPAQ). The result of the questionnaire will be converted into MET minutes
Medication Adherence
Medication adherence is measured using Morisky Medication Adherence Scale (MMAS)-8 questionnaire. The questionnaire contained 8 items, and each subject scored 1-8. Interpretation of the questionnaire is as follows: 8=high adherence, 7=medium adherence, ≤6=low adherence
Heart Disease Fact Questionnaire (HDFQ)
HDFQ is a questionnaire measuring patient's knowledge regarding coronary heart disease risk factor
Sodium Consumption
Sodium consumption is measured using WHO STEPS questionnaire
Indirect Cost
Indirect cost is defined as the cost used for transportation, consumption, accommodation, and caregiver hiring purposes. The data is gathered from direct interviews with subjects using the standardized instrument that had been prepared. The components are transportation, consumption, medical devices purchase, house renovation to foster medical necessities, caregiver fees, and loss of opportunity cost (the wage that should have been received if the subject works)
Quality-adjusted Life Years (QALYs)
QALYs are defined as the measure of health outcomes used to discover the effect of the intervention toward cost-effective analysis. This measurement is calculated by estimating the years of life remaining for a patient following a particular treatment or intervention multiplied by the changes in health quality caused by the intervention using the EQ-5D-5L questionnaire.
Cost-Utility Analysis
Cost-utility analysis is defined as incremental cost-effectiveness ratio (ICER), which is the absolute value calculated from the differences in cost between intervention and control divided by the differences of outcomes yielded.
Direct Cost
Direct cost is defined as the cost for outpatient clinic visits, medications, supporting examinations, and interventional procedures (including percutaneous coronary intervention and coronary artery bypass graft). It is measured from data stored in the finance department and information system of the hospital.

Full Information

First Posted
November 13, 2022
Last Updated
February 21, 2023
Sponsor
National Cardiovascular Center Harapan Kita Hospital Indonesia
search

1. Study Identification

Unique Protocol Identification Number
NCT05622292
Brief Title
The Effectivity of the Mobile App "HARKIT I-Care" in Secondary Prevention in Post-ACS Patients
Official Title
The Effectivity of the Mobile App "HARKIT I-Care" in Secondary Prevention in Post Acute Coronary Syndrome Patients in National Cardiovascular Center Harapan Kita Hospital
Study Type
Interventional

2. Study Status

Record Verification Date
February 2023
Overall Recruitment Status
Recruiting
Study Start Date
June 1, 2022 (Actual)
Primary Completion Date
June 30, 2023 (Anticipated)
Study Completion Date
June 30, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
National Cardiovascular Center Harapan Kita Hospital Indonesia

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
HARKIT I-Care is a mobile application developed by the National Cardiovascular Center Harapan Kita (NCCHK) to leverage patients in achieving their targets for the secondary prevention of cardiovascular diseases. The application contains various features, including exercise tracking and reminder, medication reminder, and updated educational content on cardiovascular health. Additionally, patients can log and record their blood pressure, heart rate, smoking behavior, Quality of Life, and laboratory parameters such as blood sugar and cholesterol. Our research aims to investigate whether implementing this app in post-acute coronary syndrome patients could improve their survival rate, hospitalization rate, medication adherence, and Quality of Life, along with improving their laboratory parameters to be within desirable targets.
Detailed Description
Design: This study is a single-blinded, randomized clinical trial conducted in the National Cardiovascular Center Harapan Kita, and aims to investigate the effect of the mobile application "HARKIT I-Care" on the morbidity and mortality of post-acute coronary syndrome patients. Subjects: Post-ACS patients hospitalized at the National Cardiovascular Center who are willing to be a subject in this research and have signed the informed consent form. Eligible subjects will be recruited and randomized to two groups: I-Care and control. Subjects in the I-Care group will be instructed to download 'HARKIT I-Care' application on their smartphone. Subjects will then be taught how to use the application, including logging blood pressure, blood sugar, and cholesterol levels, making use of exercise and medication reminders, and where to access health information and teleconsultation. Subjects are instructed to log their health parameters regularly according to the guidebook that has been prepared beforehand. Subjects in the control group will receive education on medication compliance and health information at the beginning of the enrolment. Education was conducted by another research team not involved in assessing outcomes. Randomization: We conducted stratified permutated block random sampling using a computer application. Stratification used were: (1) Gender: male and female, (2) Age: <65 and ≥65, and (3) Diagnosis: STEMI (ST-Elevation Myocardial Infarction), NSTEMI (Non-ST-segment Elevation Myocardial Infarction), and UAP (Unstable Angina Pectoris). Randomization was conducted using a computer app, and patient assignments were done using a sealed opaque envelope containing the assignment group. Randomization was conducted by a study statistician not involved in data collection. Outcome assessors were blinded to the treatment. Statistical Analysis plan: We planned on conducting a survival analysis for MACE (major adverse cardiovascular events), cardiovascular mortality, all-cause mortality, and rehospitalization rate. We also intended to analyze the effect of HARKIT I-Care on medication compliance, laboratory parameters, smoking cessation and relapse, sodium consumption, and physical activity.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome
Keywords
Acute Coronary Syndrome, Mobile Health, Secondary Prevention

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
This study is a single-blind, randomized, controlled clinical trial
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
60 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Control
Arm Type
No Intervention
Arm Description
Subjects in the control group will receive education on the day of enrolment in NCCHK. Subjects are instructed to take medications and conduct hospital visits as usual.
Arm Title
I-Care
Arm Type
Experimental
Arm Description
Subjects will be instructed to download the "HARKIT I-Care" app from the google play store on their smartphones. Then, they will be guided to create an account and explained how to use the application, including how to log their progress (laboratory parameters and exercise tracking) and how to see messages from their physician. All follow-ups regarding treatment progress, education, and reminders will be done through the app. Patients are directed to conduct hospital visits once per month, where patients will be prescribed cardiovascular medications according to their current condition.
Intervention Type
Device
Intervention Name(s)
HARKIT I-Care Application
Intervention Description
HARKIT I-Care Application is an application available in the google play store. The application is specifically developed for the secondary prevention of cardiovascular disease. The features included in the application are (1) Health information logging, (2) Health information education, and (3) Teleconsultation with a cardiologist. Information that can be logged includes smoking behavior, medications, weight, blood sugar level, blood pressure, cholesterol level, physical activity, and Quality of life. Educational content can be accessed by patients in the form of articles and short videos.
Primary Outcome Measure Information:
Title
Major Adverse Cardiovascular Event
Description
Major Adverse Cardiovascular Event (MACE) is described as all cardiovascular deaths, myocardial infarction, stroke, heart failure hospitalization, and revascularization event
Time Frame
6 months
Title
All-Cause Mortality
Description
All deaths, both cardiovascular mortality and non-cardiovascular mortality
Time Frame
6 months
Title
Cardiovascular Mortality
Description
We defined Cardiovascular Mortality as all deaths, excluding deaths which etiology definitely was a non-cardiovascular etiology
Time Frame
6 months
Title
Rehospitalization
Description
Rehospitalization is defined as all unplanned visits to the hospital, both to the emergency department or inpatient ward, with the diagnosis of cardiovascular diseases and related complications (bleeding, hypertension crisis, and hyperglycemia crisis). Events of the planned visit to the hospital are excluded.
Time Frame
6 months
Secondary Outcome Measure Information:
Title
Smoking Cessation
Description
Smoking cessation is defined as the number of patients who at the time of recruitment are active smokers and at the time of final follow up the patients have stopped smoking for at least one month
Time Frame
6 months
Title
Smoking Relapse
Description
Smoking relapse is defined as patient who at the time of recruitment is an ex smoker (defined as at least 1 month smoke-free before the time of recruitment) but during follow up time picks up smoking again
Time Frame
6 months
Title
Total Cholesterol Level (mg/dL)
Description
Total Cholesterol level (in mg/dL) is measured at NCCHK laboratory
Time Frame
1, 3, and 6 months
Title
HDL Level (mg/dL)
Description
HDL level (in mg/dL) is measured at NCCHK laboratory
Time Frame
1, 3, and 6 months
Title
LDL Level (mg/dL)
Description
LDL level (in mg/dL) is measured at NCCHK laboratory
Time Frame
1, 3, and 6 months
Title
Triglyceride Level (mg/dL)
Description
Triglyceride level (in mg/dL) is measured at NCCHK laboratory
Time Frame
1, 3, and 6 months
Title
Blood Glucose Level (mg/dL)
Description
Blood Glucose Level (in mg/dL) is measured at NCCHK laboratory, including fasting blood glucose and postprandial blood glucose
Time Frame
1, 3, and 6 months
Title
HbA1c (%)
Description
HbA1c (in %) is measured at NCCHK laboratory
Time Frame
1, 3, and 6 months
Title
SF-36 Quality of Life Questionnaire
Description
SF 36 is a questionnaire developed to assess the Quality of Life in patients. Each question is scored from 0-100 and transformed into different scales (Physical functioning, Role limitations due to physical health, Role limitations due to emotional problems, Energy/fatigue, emotional well-being, social functioning, pain, and general health).
Time Frame
1, 3, and 6 months
Title
Physical activity level
Description
Physical activity level is measured using the International Physical Activity Questionnaire (IPAQ). The result of the questionnaire will be converted into MET minutes
Time Frame
1, 3, and 6 months
Title
Medication Adherence
Description
Medication adherence is measured using Morisky Medication Adherence Scale (MMAS)-8 questionnaire. The questionnaire contained 8 items, and each subject scored 1-8. Interpretation of the questionnaire is as follows: 8=high adherence, 7=medium adherence, ≤6=low adherence
Time Frame
1, 3, and 6 months
Title
Heart Disease Fact Questionnaire (HDFQ)
Description
HDFQ is a questionnaire measuring patient's knowledge regarding coronary heart disease risk factor
Time Frame
1, 3, and 6 months
Title
Sodium Consumption
Description
Sodium consumption is measured using WHO STEPS questionnaire
Time Frame
1, 3, and 6 months
Title
Indirect Cost
Description
Indirect cost is defined as the cost used for transportation, consumption, accommodation, and caregiver hiring purposes. The data is gathered from direct interviews with subjects using the standardized instrument that had been prepared. The components are transportation, consumption, medical devices purchase, house renovation to foster medical necessities, caregiver fees, and loss of opportunity cost (the wage that should have been received if the subject works)
Time Frame
1, 3, and 6 months
Title
Quality-adjusted Life Years (QALYs)
Description
QALYs are defined as the measure of health outcomes used to discover the effect of the intervention toward cost-effective analysis. This measurement is calculated by estimating the years of life remaining for a patient following a particular treatment or intervention multiplied by the changes in health quality caused by the intervention using the EQ-5D-5L questionnaire.
Time Frame
1, 3, and 6 months
Title
Cost-Utility Analysis
Description
Cost-utility analysis is defined as incremental cost-effectiveness ratio (ICER), which is the absolute value calculated from the differences in cost between intervention and control divided by the differences of outcomes yielded.
Time Frame
1, 3, and 6 months
Title
Direct Cost
Description
Direct cost is defined as the cost for outpatient clinic visits, medications, supporting examinations, and interventional procedures (including percutaneous coronary intervention and coronary artery bypass graft). It is measured from data stored in the finance department and information system of the hospital.
Time Frame
1, 3, and 6 months
Other Pre-specified Outcome Measures:
Title
Application Uptake
Description
Application uptake is defined as at least one day of health data logged by subject in HARKIT I-Care application
Time Frame
1, 3, and 6 months
Title
Application Adherence
Description
Application Adherence is defined as the number of patients who use the application based on the guideline provided for them for at least 12 days per month of health data logged by subject in HARKIT I-Care
Time Frame
1, 3, and 6 months
Title
Application Completion
Description
Application Completion is defined as the number of subjects who use the application for at least 6 months and recorded at the final follow-up period
Time Frame
1, 3, and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Acute Coronary Syndrome (ACS) patients, either ST-elevation myocardial infarction (STEMI), non-ST-elevation myocardial infarction (NSTEMI), or unstable angina pectoris (UAP) who have or have not undergone revascularization treatment Exclusion Criteria: Does not have or know how to operate smartphone Unable to perform a smartphone due to hearing, vision, or cognitive impairment Withdrawn consent from the research
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Bambang Dwiputra, MD
Phone
+6281371032882
Email
bambangdwiputra@gmail.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Bambang Dwiputra, MD, FIHA
Organizational Affiliation
National Cardiovascular Center Harapan Kita
Official's Role
Principal Investigator
Facility Information:
Facility Name
National Cardiovascular Center Harapan Kita Hospital Indonesia
City
Jakarta
ZIP/Postal Code
11420
Country
Indonesia
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bambang Dwiputra, MD, FIHA
Phone
021-5684085
Ext
2209
Email
bambangdwiputra@gmail.com
First Name & Middle Initial & Last Name & Degree
Kevin Triangto, MD
Phone
021-5684085
Ext
2209
Email
kevintriangto14@gmail.com

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
29878099
Citation
Szekely O, Lane DA, Lip GYH. Guideline-adherent secondary prevention post-acute coronary syndromes: the importance of patient uptake and persistence. Eur Heart J. 2018 Jul 1;39(25):2365-2367. doi: 10.1093/eurheartj/ehy308. No abstract available.
Results Reference
background
PubMed Identifier
30728864
Citation
Chow CK, Brieger D, Ryan M, Kangaharan N, Hyun KK, Briffa T. Secondary prevention therapies in acute coronary syndrome and relation to outcomes: observational study. Heart Asia. 2019 Jan 12;11(1):e011122. doi: 10.1136/heartasia-2018-011122. eCollection 2019.
Results Reference
background
PubMed Identifier
26038524
Citation
Mathews R, Peterson ED, Honeycutt E, Chin CT, Effron MB, Zettler M, Fonarow GC, Henry TD, Wang TY. Early Medication Nonadherence After Acute Myocardial Infarction: Insights into Actionable Opportunities From the TReatment with ADP receptor iNhibitorS: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) Study. Circ Cardiovasc Qual Outcomes. 2015 Jul;8(4):347-56. doi: 10.1161/CIRCOUTCOMES.114.001223. Epub 2015 Jun 2.
Results Reference
background
PubMed Identifier
27895955
Citation
Park YT. Emerging New Era of Mobile Health Technologies. Healthc Inform Res. 2016 Oct;22(4):253-254. doi: 10.4258/hir.2016.22.4.253. Epub 2016 Oct 31. No abstract available.
Results Reference
background
PubMed Identifier
29474713
Citation
Gandapur Y, Kianoush S, Kelli HM, Misra S, Urrea B, Blaha MJ, Graham G, Marvel FA, Martin SS. The role of mHealth for improving medication adherence in patients with cardiovascular disease: a systematic review. Eur Heart J Qual Care Clin Outcomes. 2016 Oct 1;2(4):237-244. doi: 10.1093/ehjqcco/qcw018.
Results Reference
background

Learn more about this trial

The Effectivity of the Mobile App "HARKIT I-Care" in Secondary Prevention in Post-ACS Patients

We'll reach out to this number within 24 hrs